10times
08 Apr 2021Ended

Transforming CNS Drug Development with Wet Lab and Imaging Biomarker Solutions

AboutSpeakersExhibitorsReviewsPhotos

Estimated Turnout

100 - 500
Delegates
Based on previous editions

Editions

Apr 2021

Frequency

Not Available
Claim event to edit details

In fact, the WHO estimates that dementia alone affects 5-8% of all individuals over 60 years of age and that cases will increase by 10 million per .. Read more year, rising to 82 million [ ]. In fact, the WHO estimates that dementia alone affects 5-8% of all individuals over 60 years of age and that cases will increase by 10 million per year, rising to 82 million cases in 2030 and 152 million in 2050. The burdens of these diseases for individuals, families and society as a whole has led to great investment from the drug development industry. “It will be extremely helpful to understand the extent to which the suggested clinical benefit of aducanumab, donanemab and other amyloid-plaque reducing treatments are associated with reductions downstream biomarker measurements like CSF p-tau and NfL. If the field could find relationships between a treatment’s clinical benefit and these or other downstream biomarker effects, it could have a major impact on the development and potential approval of all Alzheimer’s disease-modifying treatments. Peter Schueler, MD, is board certified in Neurology and in Pharmaceutical Medicine (Swiss Medical Association). After his medical education, he worked in the pharmaceutical industry and since 2000, in the CRO world, being with ICON since 2007.

  • Followers
  • [ Users who have shown interest for this Event ]
Roshini p

Roshini p

Medical laboratory technology at Sri devaraj urs medical College

Vellore, India
  • Share your Experience
  • Organizer
Logo Follow Company

Xtalks

Canada444 Total Events / 49 Upcoming Events

More Events From The Organizer